staurosporine has been researched along with Mastocytosis, Systemic in 48 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (10.42) | 29.6817 |
| 2010's | 32 (66.67) | 24.3611 |
| 2020's | 11 (22.92) | 2.80 |
| Authors | Studies |
|---|---|
| Begna, K; Elliott, MA; Farrukh, F; Gangat, N; Hook, CC; Litzow, MR; Pardanani, A; Shah, MV; Tefferi, A | 1 |
| Bulai Livideanu, C; Casassa, E; Cura, P; Godillot, C; Marguery, MC; Paul, C; Salomon, G; Sévérino-Freire, M; Tournier, E | 1 |
| Iannazzo, S; Pilkington, H; Roskell, N; Smith, S | 1 |
| Abdelmagid, MG; Al-Kali, A; Begna, KH; Farrukh, F; Gangat, N; Larsen, JT; Litzow, MR; Pardanani, A; Reichard, KK; Sher, T; Singh, A; Tefferi, A | 1 |
| Akin, C; Arock, M; Degenfeld-Schonburg, L; Galli, SJ; Gotlib, J; Hartmann, K; Horny, HP; Metcalfe, DD; Reiter, A; Smiljkovic, D; Sotlar, K; Sperr, WR; Triggiani, M; Valent, P | 1 |
| Bednarski, JJ; Carter, MC; Nieman, E; Polk, B; Voelker, D | 1 |
| Coleman, M; Fechter, L; Galinsky, I | 1 |
| George, TI; Gotlib, J; Reiter, A | 1 |
| Bolstad, B; Dahlseng Håkonsen, G; Dalhus, M; Gisselbrecht, C; Hennik, P; Herberts, C; Kaasboll, T; Meulendijks, D; Pignatti, F; Salmonson, T; Tzogani, K; Verheijen, R; Wangen, T; Yu, Y | 1 |
| Akin, C; Awan, FT; George, TI; Gotlib, J; Hartmann, K; Hermine, O; Hexner, E; Horny, HP; Kluin-Nelemans, HC; Knoll, S; Mauro, MJ; Menssen, HD; Redhu, S; Reiter, A; Sotlar, K; Valent, P | 1 |
| Akin, C; Gotlib, J; Hartmann, K; Kluin-Nelemans, HC; Reiter, A; Valent, P | 1 |
| Angelopoulou, MK; Chatzidimitriou, C; Konstantopoulos, K; Korkolopoulou, P; Lafioniatis, S; Lakiotaki, E; Pappa, V; Plata, E; Vassilakopoulos, TP | 1 |
| Gotlib, J; Shomali, W | 1 |
| Kim, ES | 1 |
| Albano, F; Bavaro, L; Calogero, R; Cavo, M; Ciceri, F; De Benedittis, C; Delledonne, M; Elena, C; Fontana, MC; Gangemi, D; Guadagnuolo, V; Haferlach, T; Mancini, M; Manfrini, M; Martinelli, G; Meggendorfer, M; Merante, S; Morigi, F; Padella, A; Pagano, L; Papayannidis, C; Poletti, G; Riccioni, L; Rondoni, M; Savini, P; Scaffidi, L; Soverini, S; Specchia, G; Tosi, P; Valent, P; Zago, E; Zanotti, R | 1 |
| Berube, C; Corless, C; Coutre, S; DeAngelo, DJ; Dutreix, C; George, TI; Gotlib, J; Graubert, TJ; Langford, C; Liedtke, M; Linder, A; Ma, J; Medeiros, B; Merker, JD; Perkins, C; Ruffie, PA; Sternberg, D; Westervelt, P | 1 |
| Akin, C; Arock, M; Blatt, K; George, TI; Gleixner, KV; Gotlib, J; Hartmann, K; Hermine, O; Horny, HP; Kluin-Nelemans, HC; Manley, PW; Peter, B; Reiter, A; Sotlar, K; Sperr, WR; Valent, P | 1 |
| Kayser, S; Levis, MJ; Schlenk, RF | 1 |
| Arock, M; Berger, D; Bibi, S; Blatt, K; Eisenwort, G; Hadzijusufovic, E; Herrmann, H; Hoermann, G; Hoffmann, T; Horny, HP; Jawhar, M; Moriggl, R; Peter, B; Reiter, A; Schwaab, J; Sotlar, K; Sperr, WR; Stefanzl, G; Valent, P; Willmann, M; Wingelhofer, B; Zuber, J | 1 |
| Abdel-Wahab, O; Barbui, T; Cortes, JE; Gale, RP; Gotlib, J; Hehlmann, R; Khoury, HJ; Koschmieder, S; Mauro, M; Mesa, R; Mughal, TI; Radich, JP; Saglio, G; Saussele, S; Van Etten, RA; Verstovek, S | 1 |
| de Monchy, JGR; Kluin-Nelemans, JC; Mulder, AB; Oude Elberink, JNG; Rosati, S; Span, LFR; van Anrooij, B | 1 |
| Falchi, L; Verstovsek, S | 1 |
| Farrell, AT; Kasamon, YL; Ko, CW; Ma, L; McKee, AE; Nie, L; Pazdur, R; Przepiorka, D; Shord, S; Subramaniam, S; Yang, Y | 1 |
| Baird, JH; Gotlib, J | 1 |
| Pardanani, A | 3 |
| Gaspar, K; Sly, N | 1 |
| Gremida, A; McCarthy, D; Mir, F | 1 |
| Martynova, A; Merchant, A; Nael, A; O Neill, C; Ramsingh, G; Yaghmour, B; Yaghmour, G | 1 |
| Blatt, K; Gleixner, KV; Hadzijusufovic, E; Peter, B; Radia, D; Reiter, A; Suppan, V; Valent, P | 1 |
| Bai, Y; Bandara, G; Brittain, E; Chan, EC; Dyer, KD; Gilfillan, AM; Klion, AD; Maric, I; Metcalfe, DD; Scott, L; Simakova, O; Wilson, TM | 1 |
| Amin, A; Bourget, P; Cabaret, L; Carvalhosa, A; Chandesris, MO; Damaj, G; Frenzel, L; Hermine, O; Hirsch, I; Lortholary, O; Merlette, C; Mogenet, A; Vidal, F | 1 |
| Metzgeroth, G; Reiter, A; Schwaab, J | 1 |
| Barra, FF; Costa, FF; de Melo Campos, P; Duarte, AS; Lorand-Metze, I; Machado-Neto, JA; Olalla Saad, ST; Rogers, HJ; Scopim-Ribeiro, R; Tabarroki, A; Tiu, RV; Traina, F; Vassalo, J; Visconte, V | 1 |
| Akin, C; Awan, FT; George, TI; Gotlib, J; Hartmann, K; Hermine, O; Hexner, E; Horny, HP; Huntsman Labed, A; Kluin-Nelemans, HC; Mauro, MJ; Reiter, A; Sotlar, K; Stanek, EJ; Sternberg, DW; Valent, P; Villeneuve, M | 1 |
| Barete, S; Besnard, S; Beyne-Rauzy, O; Bourget, P; Brouzes, C; Canioni, D; Chandesris, MO; Chantepie, S; Cherquaoui, Z; Damaj, G; Diouf, M; Dubreuil, P; Durieu, I; Durupt, S; Faure, C; Frenzel, L; Gressin, R; Gyan, E; Hamidou, M; Hanssens, K; Hermine, O; Jeandel, PY; Launay, D; Lhermitte, L; Lortholary, O; Niault, M; Ranta, D; Schiffmann, A | 1 |
| Baumgartner, C; Gleixner, KV; Gruze, A; Hadzijusufovic, E; Peter, B; Pickl, WF; Rebuzzi, L; Thaiwong, T; Valent, P; Willmann, M; Yuzbasiyan-Gurkan, V | 1 |
| Aichberger, KJ; Baumgartner, C; Cerny-Reiterer, S; Ferenc, V; Gleixner, KV; Gruze, A; Kneidinger, M; Mayerhofer, M; Mirkina, I; Peter, B; Pickl, WF; Sillaber, C; Valent, P | 1 |
| Baumgartner, C; Herrmann, H; Kneidinger, M; Krauth, MT; Mirkina, I; Valent, P | 1 |
| Castells, MC; Liu, A; Ross, JJ; Saavedra, A; Vleugels, RA | 1 |
| Gleixner, KV; Hadzijusufovic, E; Mirkina, I; Peter, B; Pickl, WF; Schuch, K; Thaiwong, T; Valent, P; Willmann, M; Yuzbasiyan-Gurkan, V | 1 |
| Brandal, S; Carter, M; Kapur, R; Lee, YN; McDevitt, MA; Mendell, JT; Metcalfe, DD; Noel, P; Takemoto, CM; Wentzel, E | 1 |
| Akin, C; DeRemer, DL; Ustun, C | 1 |
| Bennett, KL; Cerny-Reiterer, S; Gleixner, KV; Gotlib, J; Hadzijusufovic, E; Hörmann, G; Horny, HP; Mayerhofer, M; Meyer, RA; Mitterbauer-Hohendanner, G; Pickl, WF; Reiter, A; Rix, U; Superti-Furga, G; Valent, P | 1 |
| Agis, H; Aichberger, KJ; Gleixner, KV; Gruze, A; Krauth, MT; Mayerhofer, M; Müllauer, L; Pickl, WF; Selzer, E; Sillaber, C; Valent, P; Wacheck, V | 1 |
| Aichberger, KJ; Baumgartner, C; Fabbro, D; Gleixner, KV; Gruze, A; Lee, FY; Manley, PW; Mayerhofer, M; Pickl, WF; Samorapoompichit, P; Sillaber, C; Sonneck, K; Valent, P | 1 |
16 review(s) available for staurosporine and Mastocytosis, Systemic
| Article | Year |
|---|---|
Indirect treatment comparisons of avapritinib versus midostaurin for patients with advanced systemic mastocytosis.
Topics: Humans; Mastocytosis, Systemic; Pyrazoles; Pyrroles; Staurosporine; Triazines | 2022 |
New developments in diagnosis, prognostication, and treatment of advanced systemic mastocytosis.
Topics: Animals; Chromosome Aberrations; Hematopoietic Stem Cell Transplantation; Humans; Mastocytosis, Systemic; Mutation; Prognosis; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrazoles; Pyrroles; Staurosporine; Triazines | 2020 |
European Medicines Agency review of midostaurin (Rydapt) for the treatment of adult patients with acute myeloid leukaemia and systemic mastocytosis.
Topics: Administration, Oral; Adult; Antineoplastic Combined Chemotherapy Protocols; Diarrhea; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Approval; Edema; European Union; Fatigue; Female; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Male; Mastocytosis, Systemic; Middle Aged; Nausea; Protein Kinase Inhibitors; Randomized Controlled Trials as Topic; Risk Assessment; Staurosporine; Vomiting | 2019 |
Practical management of adverse events in patients with advanced systemic mastocytosis receiving midostaurin.
Topics: Humans; Mastocytosis, Systemic; Mutation; Quality of Life; Staurosporine | 2021 |
Response Criteria in Advanced Systemic Mastocytosis: Evolution in the Era of KIT Inhibitors.
Topics: Cell Proliferation; Enzyme Inhibitors; Female; Humans; Mast Cells; Mastocytosis, Systemic; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrazoles; Pyrroles; Staurosporine; Triazines | 2021 |
Midostaurin: First Global Approval.
Topics: Adolescent; Adult; Clinical Trials as Topic; Drug Approval; Humans; Leukemia, Mast-Cell; Leukemia, Myeloid, Acute; Mastocytosis, Systemic; Middle Aged; Protein Kinase Inhibitors; Staurosporine; United States; United States Food and Drug Administration; Young Adult | 2017 |
Midostaurin: a magic bullet that blocks mast cell expansion and activation.
Topics: Antineoplastic Agents; Clinical Trials, Phase II as Topic; Drug Resistance, Neoplasm; Humans; Mast Cells; Mastocytosis, Systemic; Multicenter Studies as Topic; Staurosporine | 2017 |
Midostaurin treatment in FLT3-mutated acute myeloid leukemia and systemic mastocytosis.
Topics: Adult; Animals; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Mastocytosis, Systemic; Mutation; Protein Kinase Inhibitors; Staurosporine | 2017 |
Recent advances in the genomics and therapy of BCR/ABL1-positive and -negative chronic myeloproliferative neoplasms.
Topics: Antineoplastic Agents; Calreticulin; Cardiovascular Diseases; Cell Transformation, Neoplastic; Chronic Disease; Congresses as Topic; Epigenesis, Genetic; Fusion Proteins, bcr-abl; Humans; Janus Kinase 2; Mastocytosis, Systemic; Mutation; Myeloproliferative Disorders; Protein Kinase Inhibitors; Remission Induction; Staurosporine; Translational Research, Biomedical | 2018 |
Kit Mutations: New Insights and Diagnostic Value.
Topics: Humans; Imatinib Mesylate; Mast Cells; Mastocytosis, Cutaneous; Mastocytosis, Systemic; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Skin; Staurosporine | 2018 |
Clinical Validation of KIT Inhibition in Advanced Systemic Mastocytosis.
Topics: Amino Acid Substitution; Clinical Trials as Topic; Humans; Mastocytosis, Systemic; Mutation, Missense; Proto-Oncogene Proteins c-kit; Staurosporine | 2018 |
Systemic mastocytosis in adults: 2019 update on diagnosis, risk stratification and management.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Bone Marrow; Cladribine; Disease Management; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Interferon-alpha; Interleukin-2 Receptor alpha Subunit; Mast Cells; Mastocytosis, Systemic; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Risk Assessment; Staurosporine; Survival Analysis; Transplantation, Homologous; Tryptases | 2019 |
Midostaurin for the management of FLT3-mutated acute myeloid leukemia and advanced systemic mastocytosis.
Topics: Antineoplastic Agents; Disease Management; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Mastocytosis, Systemic; Mutation; Staurosporine | 2019 |
[Systemic mastocytosis].
Topics: Biopsy, Needle; Bone Marrow; Cladribine; DNA Mutational Analysis; Humans; Interferon-alpha; Mastocytosis, Systemic; Prognosis; Proto-Oncogene Proteins c-kit; Staurosporine | 2014 |
Tyrosine kinase inhibitors in the treatment of systemic mastocytosis.
Topics: Animals; Benzamides; Dasatinib; Humans; Imatinib Mesylate; Mastocytosis, Systemic; Mutation; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines; Staurosporine; Thiazoles | 2011 |
Systemic mastocytosis in adults: 2012 Update on diagnosis, risk stratification, and management.
Topics: Adrenal Cortex Hormones; Adult; Bone Marrow Examination; Cell Lineage; Cladribine; Clinical Trials as Topic; Clone Cells; Disease Management; Disease Progression; Humans; Hydroxyurea; Immunophenotyping; Interferon-alpha; Leukemia, Mast-Cell; Mast Cells; Mastocytosis, Systemic; Mutation, Missense; Organ Specificity; Prognosis; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Risk Assessment; Staurosporine; Tryptases | 2012 |
5 trial(s) available for staurosporine and Mastocytosis, Systemic
| Article | Year |
|---|---|
Midostaurin improves quality of life and mediator-related symptoms in advanced systemic mastocytosis.
Topics: Adult; Aged; Aged, 80 and over; Disease Progression; Female; Humans; Male; Mast Cells; Mastocytosis, Systemic; Middle Aged; Protein Kinase Inhibitors; Quality of Life; Staurosporine; Treatment Outcome | 2020 |
Efficacy and safety of midostaurin in patients with advanced systemic mastocytosis: 10-year median follow-up of a phase II trial.
Topics: Adult; Aged; Female; Follow-Up Studies; Humans; Leukemia, Mast-Cell; Male; Mastocytosis, Systemic; Middle Aged; Protein Kinase Inhibitors; Staurosporine; Young Adult | 2018 |
Midostaurin in patients with indolent systemic mastocytosis: An open-label phase 2 trial.
Topics: Adult; Female; Humans; Male; Mastocytosis, Systemic; Middle Aged; Protein Kinase Inhibitors; Staurosporine; Treatment Outcome | 2018 |
Efficacy and Safety of Midostaurin in Advanced Systemic Mastocytosis.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Female; Humans; Leukemia, Mast-Cell; Male; Mastocytosis, Systemic; Middle Aged; Multivariate Analysis; Staurosporine; Survival Analysis; Treatment Outcome | 2016 |
Midostaurin in Advanced Systemic Mastocytosis.
Topics: Age of Onset; Antineoplastic Agents; Follow-Up Studies; Humans; Mastocytosis, Systemic; Multivariate Analysis; Staurosporine; Survival Rate | 2016 |
27 other study(ies) available for staurosporine and Mastocytosis, Systemic
| Article | Year |
|---|---|
Midostaurin therapy for indolent and smoldering systemic mastocytosis: Retrospective review of Mayo Clinic experience.
Topics: Humans; Mast Cells; Mastocytosis; Mastocytosis, Systemic; Retrospective Studies; Staurosporine | 2022 |
Midostaurin-induced lichenoid photoallergic reaction in a patient with systemic mastocytosis.
Topics: Humans; Lichenoid Eruptions; Mastocytosis, Systemic; Protein Kinase Inhibitors; Staurosporine | 2022 |
Midostaurin therapy for advanced systemic mastocytosis: Mayo Clinic experience in 33 consecutive cases.
Topics: Aged; Female; Humans; Leukemia, Mast-Cell; Male; Mastocytosis; Mastocytosis, Systemic; Proto-Oncogene Proteins c-kit; Retrospective Studies; Staurosporine | 2022 |
Drug-induced mast cell eradication: A novel approach to treat mast cell activation disorders?
Topics: Humans; Mast Cell Activation Disorders; Mast Cells; Mastocytosis; Mastocytosis, Systemic; Proto-Oncogene Proteins c-kit; Staurosporine | 2022 |
Hematopoietic KIT D816Y mutation presenting as in utero aggressive systemic mastocytosis with response to midostaurin.
Topics: Humans; Mastocytosis; Mastocytosis, Systemic; Mutation; Staurosporine | 2023 |
Midostaurin: Nursing Perspectives on Managing Treatment and Adverse Events in Patients With FLT3 Mutation-Positive Acute Myeloid Leukemia and Advanced Systemic Mastocytosis.
Topics: Antineoplastic Agents; Humans; Leukemia, Myeloid, Acute; Mastocytosis, Systemic; Nausea; Staurosporine; United States; Vomiting | 2019 |
Pancytopenia, eosinophilia and coagulation disorders in a patient with T-acute lymphoblastic leukemia in prolonged remission.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Biomarkers, Tumor; Blood Cell Count; Bone Marrow; Cancer Survivors; Chromosome Deletion; Chromosome Disorders; Chromosomes, Human, Pair 7; Diagnosis, Differential; Eosinophilia; Hemorrhagic Disorders; Humans; Interferon-alpha; Leukemia, Myeloid, Acute; Male; Mastocytosis, Systemic; Myelodysplastic Syndromes; Neoplasms, Second Primary; Pancytopenia; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Staurosporine; Tryptases | 2021 |
SETD2 and histone H3 lysine 36 methylation deficiency in advanced systemic mastocytosis.
Topics: Adult; Aged; Apoptosis; Cell Line, Tumor; Female; Histone-Lysine N-Methyltransferase; Histones; Humans; K562 Cells; Lysine; Male; Mast Cells; Mastocytosis; Mastocytosis, Systemic; Methylation; Middle Aged; Mutation; Prognosis; Proteasome Endopeptidase Complex; Staurosporine | 2018 |
Midostaurin (Rydapt) for AML and advanced systemic mastocytosis.
Topics: Humans; Mastocytosis, Systemic; Protein Kinase Inhibitors; Staurosporine; Treatment Outcome | 2017 |
Drug-induced inhibition of phosphorylation of STAT5 overrides drug resistance in neoplastic mast cells.
Topics: Adult; Aged; Aged, 80 and over; Animals; Apoptosis; Cell Cycle Checkpoints; Cell Line, Tumor; Dasatinib; Dogs; Drug Resistance, Neoplasm; Drug Synergism; Female; G2 Phase Cell Cycle Checkpoints; Humans; Leukemia, Mast-Cell; Male; Mast Cells; Mastocytosis, Systemic; Middle Aged; Norbornanes; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines; STAT5 Transcription Factor; Staurosporine; Tumor Suppressor Proteins; Young Adult | 2018 |
FDA Approval Summary: Midostaurin for the Treatment of Advanced Systemic Mastocytosis.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Female; Humans; Male; Mastocytosis, Systemic; Middle Aged; Staurosporine; United States; United States Food and Drug Administration | 2018 |
A Granular Approach to a Patient with Diarrhea and Flushing.
Topics: Antineoplastic Agents; Cell Degranulation; Colonic Neoplasms; Diarrhea; Flushing; Histamine H1 Antagonists; Histamine H2 Antagonists; Humans; Mast Cells; Mastocytosis, Systemic; Middle Aged; Protein Kinase Inhibitors; Staurosporine; Treatment Outcome | 2019 |
Aggressive systemic mastocytosis: midostaurin is safe, feasible and associated with durable response post-haploidentical allogeneic stem cell transplant.
Topics: Humans; Male; Mastocytosis, Systemic; Middle Aged; Staurosporine; Transplantation, Homologous | 2019 |
Synergistic growth-inhibitory effects of ponatinib and midostaurin (PKC412) on neoplastic mast cells carrying KIT D816V.
Topics: Adult; Aged; Antineoplastic Agents; Cell Line, Tumor; Drug Synergism; Female; Growth Inhibitors; Humans; Imidazoles; Male; Mastocytosis, Systemic; Middle Aged; Proto-Oncogene Proteins c-kit; Pyridazines; Staurosporine | 2013 |
KIT GNNK splice variants: expression in systemic mastocytosis and influence on the activating potential of the D816V mutation in mast cells.
Topics: Adult; Aged; Drug Resistance, Neoplasm; Enzyme Activation; Enzyme Inhibitors; Female; Gene Expression Regulation, Neoplastic; Humans; Male; Mast Cells; Mastocytosis, Systemic; Middle Aged; Mutation; Protein Isoforms; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-kit; Staurosporine | 2013 |
Liquid chromatography-tandem mass spectrometry assay for therapeutic drug monitoring of the tyrosine kinase inhibitor, midostaurin, in plasma from patients with advanced systemic mastocytosis.
Topics: Chromatography, Liquid; Drug Monitoring; Drug Stability; Humans; Linear Models; Mastocytosis, Systemic; Reproducibility of Results; Sensitivity and Specificity; Staurosporine; Tandem Mass Spectrometry | 2014 |
Familial systemic mastocytosis with germline KIT K509I mutation is sensitive to treatment with imatinib, dasatinib and PKC412.
Topics: Adult; Apoptosis; Base Sequence; Benzamides; Blotting, Western; Dasatinib; Female; Germ-Line Mutation; Humans; Imatinib Mesylate; Mastocytosis, Systemic; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines; Staurosporine; Thiazoles; Young Adult | 2014 |
Growth-inhibitory effects of four tyrosine kinase inhibitors on neoplastic feline mast cells exhibiting a Kit exon 8 ITD mutation.
Topics: Animals; Apoptosis; Base Sequence; Benzamides; Cat Diseases; Cats; Cell Proliferation; Dasatinib; DNA Primers; Exons; Female; Humans; Imatinib Mesylate; In Vitro Techniques; Male; Mast Cells; Mastocytosis, Systemic; Molecular Sequence Data; Mutation; Phosphorylation; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines; Staurosporine; Tandem Repeat Sequences; Thiazoles | 2009 |
Identification of proapoptotic Bim as a tumor suppressor in neoplastic mast cells: role of KIT D816V and effects of various targeted drugs.
Topics: Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Bcl-2-Like Protein 11; Blotting, Northern; Blotting, Western; Boronic Acids; Bortezomib; Flow Cytometry; Gene Expression; Gene Expression Regulation, Neoplastic; Genes, Tumor Suppressor; Humans; Immunohistochemistry; In Situ Nick-End Labeling; Mast Cells; Mastocytosis, Systemic; Membrane Proteins; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-kit; Pyrazines; Reverse Transcriptase Polymerase Chain Reaction; RNA, Small Interfering; Staurosporine; Transfection | 2009 |
Midostaurin (PKC412) inhibits immunoglobulin E-dependent activation and mediator release in human blood basophils and mast cells.
Topics: Antigens, CD; Basophils; Cell Line; Cell Line, Tumor; Enzyme Inhibitors; Humans; Immunoglobulin E; Inflammation Mediators; Mast Cells; Mastocytosis, Systemic; Phosphoric Diester Hydrolases; Platelet Membrane Glycoproteins; Proto-Oncogene Proteins c-kit; Pyrophosphatases; Staurosporine; Tetraspanin 30; Up-Regulation | 2009 |
Interactive medical case. A rash hypothesis.
Topics: Acetates; Adult; Anti-Inflammatory Agents; Cromolyn Sodium; Cyclopropanes; Diarrhea; Drug Therapy, Combination; Enzyme Inhibitors; Exanthema; Female; Flushing; Histamine H2 Antagonists; Humans; Leukotriene Antagonists; Mastocytosis, Systemic; Prednisone; Protein-Tyrosine Kinases; Quinolines; Ranitidine; Staurosporine; Sulfides; Tryptases; Vomiting | 2010 |
H1-receptor antagonists terfenadine and loratadine inhibit spontaneous growth of neoplastic mast cells.
Topics: Animals; Apoptosis; Blotting, Western; Caspase 3; Cats; Cell Line, Tumor; Cell Proliferation; Dasatinib; Dogs; Dose-Response Relationship, Drug; Drug Synergism; Flow Cytometry; Histamine H1 Antagonists, Non-Sedating; Humans; Inhibitory Concentration 50; Loratadine; Mastocytoma; Mastocytosis, Systemic; Proto-Oncogene Proteins c-kit; Pyrimidines; Staurosporine; Terfenadine; Thiazoles; Tumor Cells, Cultured | 2010 |
KIT signaling regulates MITF expression through miRNAs in normal and malignant mast cell proliferation.
Topics: Animals; Antineoplastic Agents; Benzamides; Cell Proliferation; Cells, Cultured; Gene Expression Regulation; Humans; Imatinib Mesylate; Mast Cells; Mastocytosis, Systemic; Mice; Mice, Inbred C57BL; Mice, Knockout; Microphthalmia-Associated Transcription Factor; MicroRNAs; NIH 3T3 Cells; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Signal Transduction; Staurosporine | 2011 |
Systemic mastocytosis in adults: 2011 update on diagnosis, risk stratification, and management.
Topics: Adult; Antineoplastic Agents; Benzamides; Bone Marrow; Cladribine; Dasatinib; Disease-Free Survival; Humans; Hydroxyurea; Imatinib Mesylate; Interferon Type I; Mast Cells; Mastocytosis, Systemic; Piperazines; Point Mutation; Proto-Oncogene Proteins c-kit; Pyrimidines; Recombinant Proteins; Risk; Staurosporine; Thiazoles | 2011 |
KIT-D816V-independent oncogenic signaling in neoplastic cells in systemic mastocytosis: role of Lyn and Btk activation and disruption by dasatinib and bosutinib.
Topics: Agammaglobulinaemia Tyrosine Kinase; Aniline Compounds; Cell Line, Tumor; Dasatinib; Drug Synergism; Gene Expression Regulation, Neoplastic; Humans; Mast Cells; Mastocytosis, Systemic; Mutation; Nitriles; Phosphorylation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyrimidines; Quinolines; Signal Transduction; src-Family Kinases; Staurosporine; Thiazoles; Tumor Cells, Cultured | 2011 |
Identification of MCL1 as a novel target in neoplastic mast cells in systemic mastocytosis: inhibition of mast cell survival by MCL1 antisense oligonucleotides and synergism with PKC412.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Base Sequence; Benzamides; Cell Line; DNA Primers; Drug Synergism; Female; Humans; Imatinib Mesylate; In Vitro Techniques; Male; Mast Cells; Mastocytosis, Systemic; Middle Aged; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasm Proteins; Oligoribonucleotides, Antisense; Piperazines; Protein Kinase C; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-bcl-2; Proto-Oncogene Proteins c-kit; Pyrimidines; RNA, Small Interfering; Staurosporine; Transfection | 2007 |
Synergistic growth-inhibitory effects of two tyrosine kinase inhibitors, dasatinib and PKC412, on neoplastic mast cells expressing the D816V-mutated oncogenic variant of KIT.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Division; Cell Survival; Dasatinib; Drug Synergism; Humans; Mast Cells; Mastocytosis, Systemic; Mutation, Missense; Neoplasm Proteins; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines; Staurosporine; Thiazoles | 2007 |